BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32160521)

  • 1. Dishevelled 1-Regulated Superpotent Cancer Stem Cells Mediate Wnt Heterogeneity and Tumor Progression in Hepatocellular Carcinoma.
    Liao WY; Hsu CC; Chan TS; Yen CJ; Chen WY; Pan HW; Tsai KK
    Stem Cell Reports; 2020 Mar; 14(3):462-477. PubMed ID: 32160521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enrichment of cancer stem cells via β-catenin contributing to the tumorigenesis of hepatocellular carcinoma.
    Pandit H; Li Y; Li X; Zhang W; Li S; Martin RCG
    BMC Cancer; 2018 Aug; 18(1):783. PubMed ID: 30075764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
    Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
    EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The differential distributions of ASPM isoforms and their roles in Wnt signaling, cell cycle progression, and pancreatic cancer prognosis.
    Hsu CC; Liao WY; Chan TS; Chen WY; Lee CT; Shan YS; Huang PJ; Hou YC; Li CR; Tsai KK
    J Pathol; 2019 Dec; 249(4):498-508. PubMed ID: 31465125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EpCAM+ Liver Cancer Stem-Like Cells Exhibiting Autocrine Wnt Signaling Potentially Originate in Cirrhotic Patients.
    Khosla R; Rastogi A; Ramakrishna G; Pamecha V; Mukhopadhyay A; Vasudevan M; Sarin SK; Trehanpati N
    Stem Cells Transl Med; 2017 Mar; 6(3):807-818. PubMed ID: 28176469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway.
    Lo RC; Leung CO; Chan KK; Ho DW; Wong CM; Lee TK; Ng IO
    Cell Death Differ; 2018 Aug; 25(8):1426-1441. PubMed ID: 29445127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dishevelled-3 phosphorylation is governed by HIPK2/PP1Cα/ITCH axis and the non-phosphorylated form promotes cancer stemness via LGR5 in hepatocellular carcinoma.
    Tsui YM; Sze KM; Tung EK; Ho DW; Lee TK; Ng IO
    Oncotarget; 2017 Jun; 8(24):39430-39442. PubMed ID: 28455968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer.
    Chan DW; Chan CY; Yam JW; Ching YP; Ng IO
    Gastroenterology; 2006 Oct; 131(4):1218-27. PubMed ID: 17030191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Small-molecule WNT Inhibitor, IC-2, Has the Potential to Suppress Liver Cancer Stem Cells.
    Seto K; Sakabe T; Itaba N; Azumi J; Oka H; Morimoto M; Umekita Y; Shiota G
    Anticancer Res; 2017 Jul; 37(7):3569-3579. PubMed ID: 28668848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBX-induced miR-5188 impairs FOXO1 to stimulate β-catenin nuclear translocation and promotes tumor stemness in hepatocellular carcinoma.
    Lin X; Zuo S; Luo R; Li Y; Yu G; Zou Y; Zhou Y; Liu Z; Liu Y; Hu Y; Xie Y; Fang W; Liu Z
    Theranostics; 2019; 9(25):7583-7598. PubMed ID: 31695788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/β-catenin signaling.
    Fan Z; Duan J; Wang L; Xiao S; Li L; Yan X; Yao W; Wu L; Zhang S; Zhang Y; Li Y; Zhu X; Hu Y; Zhang D; Jiao S; Xu X
    Cancer Lett; 2019 May; 450():132-143. PubMed ID: 30849480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOX9 is a novel cancer stem cell marker surrogated by osteopontin in human hepatocellular carcinoma.
    Kawai T; Yasuchika K; Ishii T; Miyauchi Y; Kojima H; Yamaoka R; Katayama H; Yoshitoshi EY; Ogiso S; Kita S; Yasuda K; Fukumitsu K; Komori J; Hatano E; Kawaguchi Y; Uemoto S
    Sci Rep; 2016 Jul; 6():30489. PubMed ID: 27457505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-β-catenin signaling.
    Pai VC; Hsu CC; Chan TS; Liao WY; Chuu CP; Chen WY; Li CR; Lin CY; Huang SP; Chen LT; Tsai KK
    Oncogene; 2019 Feb; 38(8):1340-1353. PubMed ID: 30266990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcription factor AP-4 promotes tumorigenic capability and activates the Wnt/β-catenin pathway in hepatocellular carcinoma.
    Song J; Xie C; Jiang L; Wu G; Zhu J; Zhang S; Tang M; Song L; Li J
    Theranostics; 2018; 8(13):3571-3583. PubMed ID: 30026867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma.
    Terris B; Cavard C; Perret C
    J Hepatol; 2010 Feb; 52(2):280-1. PubMed ID: 20006402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chitosan promotes cancer progression and stem cell properties in association with Wnt signaling in colon and hepatocellular carcinoma cells.
    Chang PH; Sekine K; Chao HM; Hsu SH; Chern E
    Sci Rep; 2017 Apr; 8():45751. PubMed ID: 28367998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Y-box binding protein-1 promotes hepatocellular carcinoma-initiating cell progression and tumorigenesis via Wnt/β-catenin pathway.
    Chao HM; Huang HX; Chang PH; Tseng KC; Miyajima A; Chern E
    Oncotarget; 2017 Jan; 8(2):2604-2616. PubMed ID: 27911878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-589-5p inhibits MAP3K8 and suppresses CD90
    Zhang X; Jiang P; Shuai L; Chen K; Li Z; Zhang Y; Jiang Y; Li X
    J Exp Clin Cancer Res; 2016 Nov; 35(1):176. PubMed ID: 27835990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASPM promotes hepatocellular carcinoma progression by activating Wnt/β-catenin signaling through antagonizing autophagy-mediated Dvl2 degradation.
    Zhang H; Yang X; Zhu L; Li Z; Zuo P; Wang P; Feng J; Mi Y; Zhang C; Xu Y; Jin G; Zhang J; Ye H
    FEBS Open Bio; 2021 Oct; 11(10):2784-2799. PubMed ID: 34428354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid.
    Qin XY; Suzuki H; Honda M; Okada H; Kaneko S; Inoue I; Ebisui E; Hashimoto K; Carninci P; Kanki K; Tatsukawa H; Ishibashi N; Masaki T; Matsuura T; Kagechika H; Toriguchi K; Hatano E; Shirakami Y; Shiota G; Shimizu M; Moriwaki H; Kojima S
    Proc Natl Acad Sci U S A; 2018 May; 115(19):4969-4974. PubMed ID: 29686061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.